Johns Hopkins Institutional Review Board

Johns Hopkins Institutional Review Board
Name	Johns Hopkins Institutional Review Board
Formation	20th century
Headquarters	Baltimore, Maryland
Parent organization	Johns Hopkins University; Johns Hopkins Medicine

Johns Hopkins Institutional Review Board is the human subjects research oversight committee associated with Johns Hopkins University and Johns Hopkins Medicine. It reviews research protocols involving human participants, ensuring compliance with federal regulations and institutional policies, and interfaces with sponsors, investigators, and regulatory agencies. The board operates within a landscape populated by academic medical centers, federal agencies, and professional societies and has played roles in high-profile clinical trials, epidemiological research, and bioethics debates.

History

The board’s origins trace to post-World War II developments in research ethics that followed controversies surrounding Nuremberg Trials, Tuskegee syphilis study, and the creation of the National Institutes of Health clinical research infrastructure. Institutional review mechanisms expanded after the publication of the Belmont Report and passage of regulations codified in the Common Rule (United States) overseen by the Office for Human Research Protections. Johns Hopkins’ oversight evolved alongside peer institutions such as Massachusetts General Hospital, Mayo Clinic, University of Pennsylvania, and Stanford University as federal grant programs from the National Science Foundation and National Cancer Institute increased clinical research volume. The board’s procedures were influenced by cases like Henrietta Lacks, controversies involving Project MKUltra, and litigation around informed consent in trials such as those at University of Chicago and Vanderbilt University Medical Center.

Organization and Governance

Governance aligns with institutional leadership at Johns Hopkins University and Johns Hopkins Hospital under the purview of executive offices including the Office of the Dean (Johns Hopkins School of Medicine) and administrative units analogous to the Office for Human Subjects Research and the Vice President for Research (Johns Hopkins University). The board coordinates with federal regulators such as the Food and Drug Administration and the Department of Health and Human Services and interacts with sponsor organizations including the National Heart, Lung, and Blood Institute, Bill & Melinda Gates Foundation, and private industry partners like Pfizer and GlaxoSmithKline. Institutional policies reflect guidance from professional bodies such as the Association of American Medical Colleges and the American Medical Association.

Membership and Composition

Membership typically includes clinician-investigators from departments such as Department of Medicine (Johns Hopkins School of Medicine), Department of Psychiatry (Johns Hopkins Hospital), Department of Pediatrics (Johns Hopkins Children's Center), as well as nonclinical members drawn from disciplines analogous to members at Harvard Medical School and Yale School of Medicine IRBs. The board’s roster comprises physicians with specialties in cardiology, oncology, and neurology and includes ethicists, biostatisticians, and community representatives similar to those engaged by Columbia University Irving Medical Center. Representatives ensure compliance with statutes like the Health Insurance Portability and Accountability Act and considerations referenced by the Institute of Medicine.

Review Process and Procedures

Protocols undergo initial administrative screening, expedited review, or full-board deliberation modeled after procedures used by IRBs at University of California, San Francisco and Duke University. Reviewers assess informed consent documents, risk–benefit analyses, recruitment materials, and data safety monitoring plans; they require reporting aligned with ClinicalTrials.gov registration and safety reporting obligations seen in trials funded by the National Cancer Institute or overseen by the World Health Organization. Investigators submit amendments, continuing reviews, and adverse event reports, while the board issues determinations such as exempt, expedited, or nonexempt findings consistent with the Federal Policy for the Protection of Human Subjects.

Policies and Compliance

Policies reflect federal regulations, institutional mandates, and guidance from agencies including the Office for Civil Rights, the Office of Research Integrity, and the Centers for Disease Control and Prevention for public health investigations. Compliance activities include audits paralleling those conducted by Johns Hopkins Bloomberg School of Public Health collaborators, conflict-of-interest evaluations like those at Imperial College London, and data security practices informed by standards from National Institute of Standards and Technology. The IRB enforces requirements concerning vulnerable populations referenced in documents from the Food and Drug Administration and international ethics frameworks such as the Declaration of Helsinki.

Human Subjects Protections and Training

The board mandates investigator training comparable to programs offered by Collaborative Institutional Training Initiative and institutional curricula found at Mount Sinai Health System and University of California, Los Angeles. Training topics include informed consent, privacy safeguards under Health Insurance Portability and Accountability Act, culturally competent recruitment modeled on initiatives at Johns Hopkins Berman Institute of Bioethics, and protections for children and pregnant participants guided by regulations associated with the Pediatric Research Equity Act and guidance from the Maternal and Child Health Bureau. The IRB collaborates with offices responsible for research integrity similar to structures at Columbia University and partners with community advisory boards akin to those used by Kaiser Permanente.

Notable Studies and Controversies

The institution’s oversight has intersected with widely reported studies and debates involving notable figures and cases such as research touching on Henrietta Lacks tissue ethics, end-of-life care controversies similar to cases at Harvard Medical School, and discussions of data sharing highlighted in work with consortia like the Human Genome Project and initiatives by National Institutes of Health. Controversies have involved media attention and legal scrutiny reminiscent of events at University of Pennsylvania and Johns Hopkins Bloomberg School of Public Health, prompting internal reviews, policy revisions, and public engagement with stakeholders including foundations like the Robert Wood Johnson Foundation and advocacy groups such as AIDS Healthcare Foundation.

Category:Johns Hopkins University Category:Institutional review boards